JNJ

154.59

+0.68%↑

ABBV

189.81

+1.12%↑

NVO

74.6

+2.39%↑

UNH

299.22

-0.23%↓

ABT

133.52

-0.04%↓

JNJ

154.59

+0.68%↑

ABBV

189.81

+1.12%↑

NVO

74.6

+2.39%↑

UNH

299.22

-0.23%↓

ABT

133.52

-0.04%↓

JNJ

154.59

+0.68%↑

ABBV

189.81

+1.12%↑

NVO

74.6

+2.39%↑

UNH

299.22

-0.23%↓

ABT

133.52

-0.04%↓

JNJ

154.59

+0.68%↑

ABBV

189.81

+1.12%↑

NVO

74.6

+2.39%↑

UNH

299.22

-0.23%↓

ABT

133.52

-0.04%↓

JNJ

154.59

+0.68%↑

ABBV

189.81

+1.12%↑

NVO

74.6

+2.39%↑

UNH

299.22

-0.23%↓

ABT

133.52

-0.04%↓

Search

Eli Lilly and Co.

Abierto

SectorSanidad

766.97 0.57

Resumen

Variación precio

24h

Actual

Mínimo

759.04

Máximo

772.32

Métricas clave

By Trading Economics

Ingresos

-6.1B

2.8B

Ventas

-804M

13B

P/B

Media del Sector

60.989

51.198

BPA

3.34

Rentabilidad por dividendo

0.8

Margen de beneficios

21.678

Empleados

47,000

EBITDA

-2B

4.2B

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+30.26% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.80%

2.40%

Próximas Ganancias

6 ago 2025

Fecha Próximo Dividendo

10 jun 2025

Próxima Fecha de Ex Dividendo

14 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-157B

671B

Apertura anterior

766.4

Cierre anterior

766.97

Noticias sobre sentimiento de mercado

By Acuity

36%

64%

119 / 380 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Eli Lilly and Co. Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

27 may 2025, 14:41 UTC

Adquisiciones, fusiones, absorciones

Eli Lilly to Acquire SiteOne Therapeutics for Up to $1 Billion

1 may 2025, 11:24 UTC

Ganancias

Eli Lilly 1Q Revenue Surges on Demand for Mounjaro, Other Weight-Loss Treatments

29 may 2025, 01:00 UTC

Principales Noticias

How Ozempic's Maker Lost Its Grip on the Obesity Market It Created -- WSJ

28 may 2025, 18:09 UTC

Ganancias

Heart Disease Could Be a Goner When These New -2-

28 may 2025, 18:09 UTC

Ganancias

Heart Disease Could Be a Goner When These New Drugs Arrive -- Barrons.com

27 may 2025, 14:02 UTC

Adquisiciones, fusiones, absorciones

Eli Lilly: SiteOne Deal Includes Phase-2-Ready STC-004 for Treatment of Pain >LLY

27 may 2025, 14:01 UTC

Adquisiciones, fusiones, absorciones

Eli Lilly: SiteOne Deal Includes Upfront, Milestone Payments >LLY

27 may 2025, 14:00 UTC

Adquisiciones, fusiones, absorciones

Eli Lilly to Buy SiteOne Therapeutics For Up to $1 Billion in Cash >LLY

27 may 2025, 14:00 UTC

Adquisiciones, fusiones, absorciones

Lilly To Expand Its Pain Pipeline With Acquisition Of SiteOne Therapeutics >LLY

20 may 2025, 14:08 UTC

Ganancias

Novo Nordisk Woes Weigh on Denmark's Economy. Here's How. -- Barrons.com

12 may 2025, 22:14 UTC

Principales Noticias

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12 may 2025, 18:45 UTC

Principales Noticias

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

12 may 2025, 17:14 UTC

Principales Noticias

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- WSJ

7 may 2025, 17:01 UTC

Principales Noticias

Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says -- Barrons.com

7 may 2025, 13:56 UTC

Ganancias

Novo Nordisk Stock Jumps After Earnings. Compounding Market's Growth Took it By Surprise -- Barrons.com

7 may 2025, 11:18 UTC

Ganancias

Novo Nordisk Stock Jumps After Earnings. It Cuts Guidance as Weight-Loss Drug Sales Slow. -- Barrons.com

7 may 2025, 09:30 UTC

Principales Noticias

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

6 may 2025, 20:30 UTC

Principales Noticias

Novo Nordisk Reports Earnings Soon. The Wegovy Manufacturer Is Scrambling to Hold Market Share. -- Barrons.com

4 may 2025, 04:05 UTC

Adquisiciones, fusiones, absorciones

UnitedHealth's Stock Is Ailing. A Bigger Business Hasn't Helped. -- Barrons.com

1 may 2025, 21:07 UTC

Charlas de Mercado

Weight-Loss Drug Competitive Pressures Hammer Eli Lilly Shares -- Market Talk

1 may 2025, 14:07 UTC

Ganancias

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1 may 2025, 12:47 UTC

Ganancias

These Stocks Are Moving the Most Today: Microsoft, Meta, Tesla, Apple, CVS, Eli Lilly, McDonald's, Moderna, and More -- Barrons.com

1 may 2025, 12:00 UTC

Principales Noticias

Lower Taxes Could Bring More Drug Production to U.S., Says Eli Lilly CEO -- WSJ

1 may 2025, 11:58 UTC

Ganancias

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1 may 2025, 11:06 UTC

Ganancias

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1 may 2025, 10:48 UTC

Ganancias

Eli Lilly Earnings Beat Expectations. The Stock Is Falling. -- Barrons.com

1 may 2025, 10:48 UTC

Ganancias

Eli Lilly Sees FY Rev $58.0B-$61.0B >LLY

1 may 2025, 10:45 UTC

Ganancias

Eli Lilly 1Q Adj EPS $3.34 >LLY

1 may 2025, 10:45 UTC

Ganancias

Eli Lilly Sees FY EPS $20.17-EPS $21.67 >LLY

1 may 2025, 10:45 UTC

Ganancias

Eli Lilly 1Q Net $2.76B >LLY

Comparación entre iguales

Cambio de precio

Eli Lilly and Co. previsión

Precio Objetivo

By TipRanks

30.26% repunte

Estimación a 12 Meses

Media 997.6 USD  30.26%

Máximo 1,190 USD

Mínimo 700 USD

De acuerdo con 20 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Eli Lilly and Co. Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

20 ratings

17

Comprar

2

Mantener

1

Vender

Puntuación técnica

By Trading Central

N/A / 884.54Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Strong Bearish Evidence

Sentimiento

By Acuity

119 / 380 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.